home / stock / hls:cc / hls:cc quote
Last: | $12.83 |
---|---|
Change Percent: | -0.7% |
Open: | $12.92 |
Close: | $12.92 |
High: | $13.01 |
Low: | $12.8 |
Volume: | 19,683 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$12.83 | $12.92 | $12.92 | $13.01 | $12.8 | 19,683 | 08-02-2022 |
$13.65 | $13.53 | $13.65 | $13.87 | $13.52 | 7,310 | 05-06-2022 |
$13.75 | $13.7 | $13.75 | $13.83 | $13.5 | 44,918 | 05-05-2022 |
$13.755 | $13.53 | $13.755 | $13.8 | $13.5 | 7,124 | 05-04-2022 |
$13.48 | $13.85 | $13.48 | $13.88 | $13.42 | 24,007 | 05-03-2022 |
$13.38 | $13.73 | $13.38 | $13.75 | $13.38 | 11,244 | 05-02-2022 |
$13.7 | $14.43 | $13.7 | $14.43 | $13.7 | 24,625 | 04-29-2022 |
$13.84 | $14.06 | $13.84 | $14.06 | $13.83 | 16,673 | 04-28-2022 |
$13.81 | $14.38 | $13.81 | $14.38 | $13.76 | 54,042 | 04-27-2022 |
$14.79 | $15 | $14.79 | $15.46 | $14.69 | 62,852 | 04-26-2022 |
$14.71 | $14.51 | $14.71 | $14.71 | $14.1 | 6,009 | 04-25-2022 |
$14.53 | $14.1 | $14.53 | $14.72 | $14.1 | 2,868 | 04-22-2022 |
$14.88 | $15.22 | $14.88 | $15.22 | $14.49 | 19,571 | 04-21-2022 |
$15.16 | $15.25 | $15.16 | $15.41 | $15.16 | 6,878 | 04-20-2022 |
$15.15 | $15.18 | $15.15 | $15.27 | $15.11 | 13,322 | 04-19-2022 |
$15.15 | $15.21 | $15.15 | $15.26 | $15.12 | 6,359 | 04-18-2022 |
$15.25 | $15.11 | $15.25 | $15.25 | $15.11 | 1,956 | 04-15-2022 |
$15.25 | $15.11 | $15.25 | $15.25 | $15.11 | 1,956 | 04-14-2022 |
$14.96 | $15.05 | $14.96 | $15.07 | $14.91 | 17,535 | 04-13-2022 |
$15.09 | $15.07 | $15.09 | $15.27 | $15 | 2,101 | 04-12-2022 |
News, Short Squeeze, Breakout and More Instantly...
HLS Therapeutics Inc. Company Name:
HLS:CC Stock Symbol:
TSXC Market:
HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call Canada NewsWire TORONTO , April 25, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 fiscal 2024 financial results on Thursday...
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference Canada NewsWire TORONTO , April 9, 2024 /CNW/ - HLS Therapeutics I...
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups Canada NewsWire Findings Presented on VASCEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels Lp...